VERA · ISSUER CIK 1831828
Vera Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 3 Vera Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $1.3M of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 2 of 2 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$1.3MInsider selling
−$1.3MNet open-market
Sep 17, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 202616:28 | Sep 15, 2026 | VERA | PRESIDENT AND CEO, Director | S · Sell10b5-1 | $37.00 | −18,500 | 235,244 | -7% | −$685K | ||
| Sep 17, 202616:28 | Sep 15, 2026 | VERA | PRESIDENT AND CEO, Director | M · Exercise10b5-1 | $2.90 | +18,500 | 253,744 | +8% | $54K | ||
| Sep 14, 202616:28 | Sep 11, 2026 | VERA | SVP, FINANCE, CHIEF ACCT OFFCR | M · Exercise | $3.94 | +5,000 | 80,754 | +7% | $20K | ||
| Sep 4, 202616:15 | Sep 2, 2026 | VERA | PRESIDENT AND CEO, Director | S · Sell10b5-1 | $35.12 | −18,500 | 235,244 | -7% | −$650K | ||
| Sep 4, 202616:15 | Sep 2, 2026 | VERA | PRESIDENT AND CEO, Director | M · Exercise10b5-1 | $2.90 | +18,500 | 253,744 | +8% | $54K | ||
| Aug 5, 202616:14 | Aug 3, 2026 | VERA | Chief Regulatory Officer | A · Grant | — | +44,987 | 44,987 | New | — |